Program Finalized for October 2018 ISPOR Summit on Value Assessment and Healthcare Pricing

Published Oct 2, 2018

Speakers Include Mark McClellan, MD, PhD, Duke-Margolis Health Policy Center and John M. O'Brien, PharmD, MPH, US Department of Health & Human Services

Lawrenceville, NJ, USA—October 2, 2018—ISPOR, the professional society for health economics and outcomes research, announced the full program and speakers for the upcoming ISPOR Summit 2018, “New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare,” scheduled for October 19, 2018 in Washington, DC, USA. The Summit is timely as healthcare pricing, particularly drug pricing, faces greater scrutiny and healthcare costs continue to increase year after year. Summit sessions will examine various approaches to measuring value and explore how these value assessments could be used in pricing and coverage decisions. This Summit will complement the recently published work by the ISPOR Special Task Force for the Initiative on US Value Assessment Frameworks by creating a forum for discussion of the research agenda and current initiatives. By convening a broad range of stakeholders, the Summit will focus on how pricing could better reflect the value that patients and society as a whole derive from healthcare. Mark McClellan, MD, PhD, Director of the Duke-Margolis Center for Health Policy and former US FDA Commissioner and CMS Administrator will provide the keynote address for the Summit. Recently confirmed as a speaker for the final session, “Practical Next Steps in Improving Value Measurement and Use,” is John M. O'Brien, PharmD, MPH. Dr O’Brien is Deputy Assistant Secretary at the US Department of Health and Human Services. Duke-Margolis Center for Health Policy is also a supporter of the Summit. Summit Program: Keynote Address
  • Mark McClellan, MD, PhD, Duke-Margolis Center for Health Policy and former US FDA Commissioner and CMS Administrator
Current Value Frameworks—What’s New?
  • Rick Chapman, PhD, MS, Health Economics Institute for Clinical and Economics Research
  • Patrick Gleason, PharmD, Prime Therapeutics
  • Lowell Schnipper, MD, Beth Israel Deaconess Medical Center
  • Josh Seidman, PhD, MHS, Avalere Health
  • Moderated by Richard Willke, PhD, ISPOR
Novel Approaches to Value Assessment, Within the Cost-Effectiveness Framework
  • Jaime Caro, MDCM, Evidera
  • Susan Griffin, PhD, University of York
  • Reed Johnson, PhD, Duke University
  • Charles Phelps, PhD, University of Rochester
  • Moderated by Lou Garrison, PhD
Novel Approaches to Value Assessment, Beyond the Cost-Effectiveness Framework
  • Jaime Caro, MDCM, Evidera
  • Robert Dubois, MD, PhD, National Pharmaceutical Council
  • Reed Johnson, PhD, Duke University
  • Charles Phelps, PhD, University of Rochester
  • Moderated by Shelby Reed, PhD, Duke University,
Specific Value Assessment Considerations
  • Anirban Basu, PhD, MS, The Comparative Health Outcomes, Policy, and Economics Institute
  • Patricia Danzon, PhD, University of Pennsylvania
  • Liz Spurgin, MBA, Medical Device Innovation Consortium
  • Adrian Towse, MA, Office of Health Economics
  • Moderated by Sachin Kamal-Bahl, PhD, Pfizer
Practical Next Steps in Improving Value Measurement and Use
  • Bryan Luce, PhD, Evidera
  • Newell McElwee, PharmD, MSPH, Boehringer Ingelheim
  • John M. O'Brien, PharmD, MPH, US Department of Health and Human Services
  • Suzanne Schrandt, JD, Arthritis Foundation
  • Moderated by Dan Ollendorf, PhD, Tufts Medical Center
Registration and additional information on the Summit can be found here: Summit Information | Registration | Sponsorship Opportunities | Press

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×